Homecare Homebase has released an updated HCHB Analytics Home Health Impact Report Model, less than two weeks following CMS’ publication of the 2024 Home Health Proposed Rule.
(PRWeb July 13, 2023)
Read the full story at https://www.prweb.com/releases/homecare_homebase_releases_2024_home_health_proposed_rule_model/prweb19442221.htm
Brain lesions called enlarged perivascular spaces — a marker of small-vessel disease that can lead to stroke and dementia — have been ignored because of the difficulty of counting them on MRI scans….
(PRWeb July 13, 2023)
Read the full story at https://www.prweb.com/releases/ut_health_science_center_san_antonio_develops_tool_that_counts_brain_lesions_in_seconds/prweb19442003.htm
“I am excited to watch as the NDV-vectored vaccine platform matures to address newer variants of concern in larger randomized controlled trials.” -Sean Liu, MD, PhD
NEW YORK (PRWEB)
July 13, 2023
The Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York City is pleased to announce that CastleVax, Inc., has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
The phase 1 study evaluated two dose levels of the live, recombinant vaccine, NDV-HXP-Spike(S), delivered intranasally, intramuscularly, or via both routes in combination, in participants previously vaccinated with an authorized intramuscular COVID-19 vaccine.
Interim results show that intranasal delivery resulted in a robust S-specific, secretory IgA response in saliva relative to pre-booster levels, which is important for conferring mucosal immunity and has the potential to prevent infection and/or transmission of COVID-19. In addition, a strong boosting of serum neutralizing-antibody response was observed, which is important for conferring systemic immunity and prevention of severe disease, hospitalization, and death (the efficacy endpoint(s) for currently authorized intramuscularly delivered vaccines). The safety profile was also acceptable, successfully clearing the Data Safety Monitoring Board reviews.
“We are thrilled with the progress led by principal investigator Sean Liu, MD, PhD, and our Mount Sinai colleagues, and are both excited and encouraged by these preliminary results,” said Michael Egan, PhD, CastleVax Chief Scientific Officer and acting Chief Executive Officer. “Dr. Liu’s preliminary findings complement those of our development partners in Mexico, Avimex, whose interim phase 3 results showed their live, attenuated NDV-based vaccine (Patria® (AVX/COVID-12), licensed from CastleVax, was effective as a booster against COVID-19.”
“The initial observations from our phase 1 trial of NDV-HXP-S as a COVID-19 booster vaccination suggest that it is safe and well-tolerated when delivered intranasally and/or intramuscularly to healthy adults. The preliminary exploratory findings looking at mucosal and systemic antibody responses are encouraging, particularly when NDV-HXP-S is administered intranasally. There is a growing interest in developing vaccines that not only protect against the severe illnesses caused by respiratory pathogens but also limit host susceptibility and decrease person-to-person transmissions by enhancing the mucosal immune response. I am excited to watch as the NDV-vectored vaccine platform matures to address newer variants of concern in larger randomized controlled trials,” said Sean Liu, MD, PhD, Assistant Professor of Medicine (Infectious Diseases, and Hospital Medicine) at the Icahn School of Medicine at Mount Sinai.
The NDV-vectored vaccine platform was developed by Peter Palese, PhD, Horace W. Goldsmith Professor and Chair of Microbiology; Adolfo García-Sastre, PhD, Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Global Health and Emerging Pathogens Institute; and Florian Krammer, PhD, Professor of Microbiology, and Pathology, Molecular and Cell Based Medicine, at Icahn Mount Sinai, and was licensed by Mount Sinai to CastleVax Inc. Mount Sinai has a financial interest in this technology and in CastleVax. Drs. Palese, García-Sastre, and Krammer, and Weina Sun, PhD, Assistant Professor of Microbiology, also have a financial interest in this technology and in CastleVax pursuant to the Mount Sinai Intellectual Property Policy. Mount Sinai is represented on the CastleVax Board of Directors by Erik Lium, PhD, Chief Commercial Innovation Officer, Mount Sinai Health System, and President, Mount Sinai Innovation Partners; Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System; Matthew Rosamond, Chief Financial Officer, Icahn Mount Sinai; and Stephen Harvey, MBA, Chief Financial Officer, Mount Sinai Health System. The phase 1 trial mentioned above is led by independent faculty investigators (Dr. Liu and Judith A. Aberg, MD, Chief of the Division of Infectious Diseases, Mount Sinai Health System) who have no financial interests in the vaccine or with CastleVax.
About NDV-HXP-S: The NDV-based vaccine technology was developed at Icahn Mount Sinai in the laboratories of Drs. Palese, García-Sastre, and Krammer. HexaPro (HXP) was developed at UT Austin.
About CastleVax
In August 2022, the Mount Sinai Health System launched CastleVax, Inc., a clinical-stage vaccine research and development company devoted to the commercial development of the NDV vaccine platform technology.
For more information on CastleVax and the NDV vaccine platform, visit https://www.castlevax.com.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators and clinicians work within and across 34 academic departments and 35 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
Coalition for Family Harmony
The Mobile Medical Unit will give survivors the opportunity to take care of their medical needs in a safe and confidential location.
OXNARD, Calif. (PRWEB)
July 13, 2023
Coalition for Family Harmony (Coalition), which serves survivors of domestic violence in Ventura County, has been awarded a grant through the California Office of Emergency Services to provide mobile health care services to domestic violence emergency shelters in Ventura County.
The Coalition is contracting with Dr. Mohammed Rezai from the Mobile Wellness Clinic to provide services. Dr. Rezai is a double board-certified physician in family medicine and addiction medicine.
The mobile medical unit will provide services such as:
-COVID-19 vaccines
-COVID-19 testing
-Post-acute COVID-19 care (e.g., education, rehabilitation, prevention, treatment, and support services for symptoms occurring after recovery from acute COVID-19 infection)
-Primary health care (e.g., wellness checks, health exams, referrals)
“We understand that survivors of Domestic Violence do not prioritize their health. The Mobile Medical Unit will give survivors the opportunity to take care of their medical needs in a safe and confidential location,” said Caroline Prijatel-Sutton, Psy.D, Executive Director, Coalition for Family Harmony.
The mobile health care services grant is important for the Coalition to continue its momentum and great efforts of improving the quality of life and creating hope for survivors of domestic violence and sexual assault.
For more information, please visit http://www.thecoalition.org.
About Coalition for Family Harmony
Since 1976, Coalition for Family Harmony has served survivors of domestic violence and sexual assault in Ventura County. The Coalition’s mission is to provide direct services to victims of domestic violence and sexual assault; to educate the community regarding multiple forms of violence; and to prevent the cycle of violence. Since its inception, Coalition has helped save thousands of lives and stop the deadly cycle of violence in families.
Survivors may call our 24-hour trilingual hotline at 800-300-2181.
Share article on social media or email:
To date, the Lustgarten Foundation has funded more than $250 million in research grants and has been a leading force in every major advancement in pancreatic cancer research.
“The appointment of Dr. Vickers and Dr. Penberthy will undoubtedly propel us forward in our mission to transform pancreatic cancer into a curable disease,” said Linda Tantawi, CEO of the Lustgarten Foundation.
WOODBURY, N.Y. (PRWEB)
July 13, 2023
The Lustgarten Foundation, the nation’s largest private funder of pancreatic cancer research, today announced the appointment of two new board members: Selwyn M. Vickers, MD, FACS, and Scott Penberthy, PhD, MS. Dr. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. Dr. Penberthy is a visionary engineering leader with extensive expertise in artificial intelligence (AI) and technology, specifically in the healthcare space.
“We are honored to welcome Dr. Vickers and Dr. Penberthy to the Lustgarten Foundation Board of Directors,” said Linda Tantawi, CEO of the Lustgarten Foundation. “At the Foundation, we firmly believe in the fundamental role of innovative and cutting-edge research in solving the complexities of pancreatic cancer. The appointment of Dr. Vickers and Dr. Penberthy will undoubtedly propel us forward in our mission to transform pancreatic cancer into a curable disease.”
Selwyn M. Vickers, MD, FACS, a renowned pancreatic cancer surgeon, researcher, and academic medical leader, is the President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK). Prior to joining MSK, Dr. Vickers was the CEO of the University of Alabama at Birmingham (UAB) and the Senior Vice President and Dean of the UAB Marnix E. Heersink School of Medicine. He also served as the Jay Phillips Professor of Surgery and Chair of the Department of Surgery at the University of Minnesota Medical School. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars and has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Additionally, he has served as President of the Society for Surgery of the Alimentary Tract and the Southern Surgical Association. Dr. Vickers is the immediate Past President of the American Surgical Association.
“The work of the Lustgarten Foundation plays an essential role in propelling pancreatic research forward,” said Dr. Vickers, “I look forward to the work we will do together to continue to advance treatments and support those impacted by this devastating disease.”
Scott Penberthy, PhD, MS is the Managing Director of Applied AI in Google Cloud’s Office of the CTO. Prior to his tenure at Google, he served as the Managing Director of Technology at PwC, where he led a comprehensive company-wide digital transformation and spearheaded the introduction of AI and cloud services. Having lost his mom to breast cancer when she was only 57, Dr. Penberthy promised her to find a better way to treat cancer. At Google, with the assignment to figure out how AI can do good in the world, Dr. Penberthy started to look at cancer as a programming problem, a pattern gone wrong, which means we can learn to fix it. Dr. Penberthy serves on numerous Boards of Advisors, including Stanford University’s Institute for Computational & Mathematical Engineering.
“I’m delighted to join the fight to end cancer as we know it, shifting from a lethal diagnosis to one that can be managed,” said Scott Penberthy. “We need all the help we can get from AI and cloud! Pancreatic cancer is one of the most challenging, complex, and subtle diseases, and I firmly believe that contributions here will extend to all others.”
About Lustgarten Foundation
The Lustgarten Foundation funds the world’s preeminent pancreatic cancer researchers, driving the pursuit of bold and innovative science toward earlier detection, better treatments and transforming pancreatic cancer into a curable disease. Our mission is rooted in the belief that research is fundamental, in fact, it is the only way to produce real results. The Lustgarten Foundation is a catalyst in the field of pancreatic cancer research. Lustgarten-funded science has been a driving force in every major advancement in pancreatic cancer research since 1998. We believe time is everything for pancreatic cancer patients and their families. The Foundation funds research where creative risks yield high rewards to accelerate and expand life-saving treatment options. And we believe in the power of community. Lustgarten programs and events provide people affected by pancreatic cancer a voice and a place to create hope, together. The Lustgarten Foundation is the largest private funder of pancreatic cancer research and 100% of all donations fuel the research to advance understanding of this complex, devastating and historically underfunded cancer. For more information, visit http://www.lustgarten.org.
Share article on social media or email:
“Patients can’t wait for better care. This release furthers our mission to accelerate the work of MA teams and inform medical decision-making that can get the right treatments to the right patients, faster than ever before,” said Dipanwita Das, CEO and Co-founder, Sorcero.
WASHINGTON (PRWEB)
July 13, 2023
Sorcero, the leading provider of advanced AI solutions purpose-built for Life Sciences organizations, today announced an exciting new release of the Sorcero AI Platform. The solution enables Medical Affairs (MA) Teams to now to unify stakeholder data and accelerate data-driven decisions across the asset lifecycle. In particular, Sorcero now provides life sciences companies with an omnichannel view of the healthcare provider (HCP) journey across all touchpoints, critical to informing and planning Key Opinion Leader (KOL) engagement strategies. These new features are now available on the platform and via the Google Cloud Marketplace.
As Medical Affairs steps into a more prominent strategic role, they need to rely on better data and analytics to drive the decisions they make and the evidence they share with the medical field and to their organizations. Sorcero’s medically-tuned AI leverages advanced algorithms and disease-focused ontologies to organize and understand how language is used in Life Sciences. Uniquely qualified to augment the MA mission, its patented technology delivers unprecedented accuracy on scientific content, delivered in an enterprise-grade compliant environment.
Sorcero’s Summer 2023 release includes:
The Sorcero AI Platform includes three products, Sorcero IPM™, Sorcero MIM™, and Sorcero PLS™ .
Sorcero IPM (Intelligent Publication Management) captures and analyzes biomedical content from the world’s largest dataset of open-access scientific sources to identify the most clinically impactful content for competitive intelligence, compliance, and evidence generation.
Sorcero MIM (Medical Insight Management) revolutionizes the way Medical Affairs teams work by unifying information across all internal and external data sources and providing a single point of access to relevant topics that are tagged and organized by key details. Our AI-powered solution removes information silos and delivers 300% more insight data while reducing time to surface emerging trends from weeks to minutes.
Sorcero PLS (Plain Language Summaries) Service, enables life sciences organizations to reach broader audiences by compacting complex scientific and medical data into easily understandable language that meets new regulations and drives scientific engagement by over 16x.
About Sorcero
Sorcero gives Life Sciences companies the unparalleled ability to generate measurable and actionable insights across all external and internal medical data. The unique ability to unify and enrich unstructured and structured data across a disparate set of sources, with advanced biomedical AI, enables teams to make confident decisions with a complete view of healthcare data. With the Sorcero AI Platform, teams can drive product adoption and improve patient outcomes with precision and confidence up to 12x faster. We believe the most important application of AI today is to speed patient access to breakthrough treatments. Founded in 2018, Sorcero is privately held and headquartered in Washington, DC and has raised over $20M in Series A funding from CityRock Ventures, Harmonix, Leawood Venture Capital, Mighty Capital, Rackhouse, and Castor Ventures. For more information, visit http://www.Sorcero.com.
Share article on social media or email:
Save the Date
“As an independent agency, it’s easy to feel like you are on an island experiencing the world of home care alone. Having the opportunity to come together to meet owners from all over really showed me we all have similar experiences,” says Kelly Adams, CSA® and owner of Beyond Home Care.
BRENTWOOD, Tenn. (PRWEB)
July 13, 2023
DecisionHealth, an HCPro brand, is excited to announce its annual Private Duty National Conference and Expo will be held November 12–14, 2023, at the Horseshoe Las Vegas. This is the largest national event for private duty executives to network and hear firsthand success stories from top-performing agencies. Attendees will learn how to successfully generate referrals, provide quality care, and accelerate growth while capturing market share.
When asked what she’s looking forward to most at this year’sconference and expo, speaker Kelly Adams, certified senior advisor (CSA)® and owner of Beyond Home Care, said, “As an
independent agency, it’s easy to feel like you are on an island experiencing the world of home care alone. Having the opportunity to come together to meet owners from all over really showed me we all have similar experiences and I found so much value in connecting with this community!”
Here’s just a sampling of what’s included on the 2023 agenda:
There will be ample networking opportunities for attendees to connect with like-minded executives to find their own niche and browse the exhibit hall filled with dozens of the latest solutions.
Speaker Michelle Cone, senior vice president of training and brand programs at HomeWell Franchising Inc., adds, “I always look forward to being amongst friends and receiving relevant tools, resources, best practices, and industry insights that you can execute immediately to increase your market share, improve your recruitment and retention efforts, and drive profitability. If you are a non-medical home care owner, operator, administrator, recruiter or other key associate, you do not want to miss this opportunity.”
Register by visiting https://decisionhealth.com/PDN2023.
Early bird pricing and group rates are available. Contact a Customer Service representative at 1-855-225-5341, or e-mail HCevents@hcpro.com.
About DecisionHealth
DecisionHealth, an HCPro brand, is the industry’s leading source for home health agencies and medical practice facilities to receive the latest news, analysis, and regulatory guidance on Medicare coding and reimbursement, benchmarks, payments, and Health Insurance Portability and Accountability Act (HIPAA) compliance through its flagship publications, as well as a wide selection of coding books, educational events, and online tools. Visit http://www.decisionhealth.com.
About HCPro
For over 34 years, HCPro, a division of Simplify Compliance LLC, has specialized in providing the latest healthcare regulatory information through industry-leading publications, continuing education, online coding platforms, instructor-led training, events, consulting services, and more to deliver consistent training, achieve compliance, and maximize workflow efficiencies, resulting in measurable performance and financial improvements. Visit http://www.hcpro.com/.
Share article on social media or email:
The partnership will see PRIMR's content featured on the ClinOne platform, effectively boosting engagement for both healthcare providers and potential trial participants.
(PRWeb July 13, 2023)
Read the full story at https://www.prweb.com/releases/clinone_and_primr_join_forces_to_enhance_clinical_trial_engagement/prweb19440258.htm
Fellows will receive professional development and training in how to navigate the demands and politics of academic life, ensure that their research reflects the real world racial, gender, and cultural…
(PRWeb July 13, 2023)
Read the full story at https://www.prweb.com/releases/fenway_health_announces_inaugural_cohort_of_kenneth_h_mayer_fellows/prweb19440664.htm
We selected Genedata Biologics because of its unique workflow and registration engine that supports processes from candidate selection all the way through IND filings and commercialization. Ann Cheung, Ph.D., Head of Research at Dragonfly Therapeutics
BASEL, Switzerland (PRWEB)
July 13, 2023
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Dragonfly Therapeutics, a clinical-stage biotechnology company developing novel immunotherapies, is using the Genedata Biologics® integrated R&D workflow platform. The platform supports Dragonfly’s development of novel multi-specific therapies designed as natural combinations harnessing NK cells, γδ T cells, CD8+ T cells, and other cells of the innate and adaptive immune system, to provide a unique therapeutic window beyond current therapies for treatment of cancer and chronic inflammatory diseases.
“We selected Genedata Biologics because of its unique workflow and registration engine that supports processes from candidate selection all the way through IND filings and commercialization,” said Ann Cheung, Ph.D., Head of Research at Dragonfly Therapeutics. “It was important to us to put workflows in place that can give us out-of-the-box support for our novel R&D programs. Genedata has an excellent reputation and notable ability to develop innovative digital solutions that are purpose-built for biotherapeutic R&D.”
Genedata Biologics is a first-in-class workflow system that streamlines discovery of biotherapeutics of any format, including bi- and multi-specifics, adoptive cell therapies, gene therapies, and RNA. Uniquely designed from the start to digitalize biotherapeutic discovery, the platform facilitates and automates complex R&D processes. Genedata Biologics acts as a central end-to-end data backbone that integrates all R&D processes from molecular biology, screening, engineering, expression, purification, and analytics, to candidate developability and manufacturability assessments. Real-time access to all data enables users at all levels of an organization to rapidly make more informed decisions, as well as to analyze data patterns that drive future discovery programs.
“By providing Dragonfly Therapeutics with a central data backbone for their discovery pipeline, we are making their R&D faster and more efficient,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Our technology, combined with Dragonfly’s unique scientific approach, will bring cutting-edge therapeutics to patients faster and help them live better and longer lives.”
Since its first release in 2011, Genedata Biologics has been rapidly adopted by most of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and rollout and deployment support.
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing therapies that use its novel bispecific antibody technology to harness the body’s immune system to bring breakthrough treatments to patients. In addition to its wholly-owned clinical assets and multiple assets in the clinic with partners, Dragonfly has a deep pipeline of wholly-owned preclinical candidates developed using its proprietary platforms as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
http://www.dragonflytx.com
LinkedIn | Twitter
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com
LinkedIn | Twitter | YouTube
________________________________________
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Share article on social media or email:
